Navigation Links
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
Date:12/11/2007

eived a median of 22 months of treatment.

Hemolysis was significantly reduced with eculizumab treatment in patients with all levels of baseline hemolysis. In patients with the lowest quartile of hemolysis (< 1490 U/L), LDH was reduced from 1077 +/- 42 U/L pre-eculizumab to 323 +/- 22 U/L during the first six months and to 347 +/- 47 U/L during the most recent six months of Soliris therapy (P<0.001 for each comparison to baseline). Hemolysis was also significantly reduced during both the first and most recent six months of Soliris therapy in patients with mild anemia (Hgb of greater than or equal to 10.5 g/L) and minimal transfusion support prior to treatment (0 or 1 transfusion episode in the previous year) (P<0.001 for all subgroups at both time intervals).

In the study, patients who might have been considered to have less severe disease were found to have an elevated risk of blood clots prior to therapy and experienced the following reductions in the incidence of blood clots during Soliris therapy: for patients with the lowest quartile of baseline hemolysis, the rate decreased from 10.8 to 4.5 events per 100 patient years (P=0.009, n=48), for those with mild anemia from 5.2 to 0.8 events per 100 patient years (P<0.001, n=55), and for those with minimal pretreatment transfusion support from 4.9 to 0.0 events per 100 patient years (P=0.063, n=22).

Soliris treatment was associated with significant improvements in fatigue (as measured by the FACIT-Fatigue instrument), regardless of the baseline level of hemolysis, anemia, or pretreatment transfusion requirements. At baseline, patients who had the lowest levels of hemolysis, mild anemia, or minimal transfusion requirements reported fatigue. With patients in the lowest quartile of baseline hemolysis, FACIT-Fatigue scores improved by 6 points during the first six months and by 8 points during the most recent six months of Soliris therapy (P<0.001 for each comparison to baseline); an increase of 3 or
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... DIEGO , Oct. 20, 2014 ... industry leader in bioactive lipid-targeted therapeutics, received official notification ... has been granted another key patent supporting its ... newly issued patent, European patent No. 2087002, claims ... substance in Lpath,s two lead compounds, iSONEP and ...
(Date:10/20/2014)... Mary,s Medicinals today announced that its 501(c)(3) foundation, ... Operation Grow4Vets , a national, nonpartisan organization focused ... to assist them in living with injuries sustained while ... , An ever-increasing number of medical studies have shown ... pain, Post-traumatic Stress Disorder (PTSD) and Traumatic Brain Injury ...
(Date:10/20/2014)... N.C., Oct. 20, 2014  BioPontis Alliance for ... both philanthropies, announced today the creation of a ... treatment of the rare disease known as Charcot- ... its alliance model earlier this month. Today,s partnership ... a collaborative model where researchers and all CMT ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3
... On July 31 , Massachusetts lawmakers passed legislation ... sentencing laws. , , , ... Drug offenders serving mandatory minimum sentences at county Houses of Correction will ... bill lawmakers voted on did not include two reforms previously endorsed by ...
... Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals ... a privately-held drug development company focused on liver disease and oncology. ... Conatus Pharmaceuticals ... of Idun Pharmaceuticals, which was acquired by Pfizer Inc. in 2005.  "The ...
Cached Medicine Technology:FAMM Applauds Massachusetts Legislature for Sentencing Reforms 2Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary 2
(Date:10/20/2014)... The Advocator Group, LLC is proud ... for Suicide Prevention’s (AFSP) Out of the Darkness walk ... that hosts hundreds of community walks throughout the country ... to help understand and prevent suicide through not only ... , The Advocator Group shares this passion for ...
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Principle Business ... takes pride in manufacturing top-of-the-line absorbent products. The ... of its most popular brand, Tranquility® Premium Protection absorbent ... a new website, gave its packaging a new look, ... the brand message to the public. , The new ...
(Date:10/20/2014)... October 20, 2014 Succeed is proud to ... companies who participated in the Every Body Walk! ... public awareness project that encourages workers to be more active ... 10,000 Program, which concluded at the end of September, was ... cities and metro areas. Participating companies gave their staff ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center ... hospital ROI on membership dues at 12.5. In other words, ... in value to member hospitals. The calculation used to determine ... , “This is the first time we’ve actually been ... methodology is really sound,” said Bill Ryan , president ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4
... highest risk, study finds , , TUESDAY, May 26 (HealthDay ... effects of alcohol, the greater your chance of becoming an alcoholic, ... sensitivity to imbibing intoxicants, called a low level of response (LR) ... get that buzz or other desired effect. The condition appears to ...
... Boston University School of Medicine (BUSM) and Boston University ... method fully resolves confounding by indication in observational studies, ... by unmeasured confounding, it is not straightforward to determine ... in obtaining a valid and precise estimate of effect. ...
... of East Asian and South Asian descent are between two ... at birth when compared to their Canadian counterparts, according to ... Ray. Dr. Ray and a team of researchers, who developed ... suggest the need to consider differences across ethnic groups to ...
... by researchers UT Southwestern Medical Center are accelerating efforts ... the world,s population. , The new findings, available online ... of the National Academy of Sciences, demonstrate that ... Caenorhabditis elegans, a common research worm, also provides the ...
... Washington, D.C. Tops List of America,s Fittest Cities SEATTLE, ... the fittest of America,s 50 most populous metropolitan areas ... American Fitness Index(TM) (AFI). ACSM unveiled the 2009 rankings ... Fitness Status of the 50 Largest Metropolitan Areas," during ...
... May 26 maxIT Healthcare LLC (maxIT), a ... the highest results in the staff augmentation category ... of the healthcare industry,s leading associations. According to ... published in February of 2009 by KLAS entitled ...
Cached Medicine News:Health News:Sensitivity to Alcohol May Predict Alcoholism 2Health News:BUSM researchers find no adjustment method fully resolves confounding by indication 2Health News:Newborns of South Asian and East Asian descent misclassified as underweight at birth: Study 2Health News:Researchers gain ground in efforts to fight parasite infection 2Health News:ACSM American Fitness Index(TM) Ranks 50 Largest Metro Areas on Health and Community Fitness 2Health News:ACSM American Fitness Index(TM) Ranks 50 Largest Metro Areas on Health and Community Fitness 3Health News:ACSM American Fitness Index(TM) Ranks 50 Largest Metro Areas on Health and Community Fitness 4Health News:ACSM American Fitness Index(TM) Ranks 50 Largest Metro Areas on Health and Community Fitness 5Health News:ACSM American Fitness Index(TM) Ranks 50 Largest Metro Areas on Health and Community Fitness 6Health News:ACSM American Fitness Index(TM) Ranks 50 Largest Metro Areas on Health and Community Fitness 7Health News:Is There a Meaningful Difference Between Healthcare IT Consulting Firms for Staff Augmentation? 2Health News:Is There a Meaningful Difference Between Healthcare IT Consulting Firms for Staff Augmentation? 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: